Nanocarriers for pulmonary administration of peptides and therapeutic proteins

被引:24
作者
Andrade, Fernanda [1 ]
Videira, Mafalda [2 ]
Ferreira, Domingos [1 ]
Sarmento, Bruno [1 ,3 ]
机构
[1] Univ Porto, Fac Pharm, Dept Pharmaceut Technol, P-4050047 Oporto, Portugal
[2] Univ Lisbon, Fac Pharm, iMed UL Res Inst Med & Pharmaceut Sci, P-1699 Lisbon, Portugal
[3] Inst Super Ciencias Saude Norte, Dept Pharmaceut Sci, CICS, Condra, Portugal
关键词
inhalation; nanocarriers; noninvasive delivery; peptides; therapeutic proteins; AEROSOLIZED CYCLOSPORINE-A; ACUTE ALLOGRAFT-REJECTION; COLONY-STIMULATING FACTOR; DRUG-DELIVERY SYSTEMS; DRY POWDER INHALATION; INHALED HUMAN INSULIN; INTRATRACHEAL INSTILLATION; INTERLEUKIN-2; LIPOSOMES; NANOCOMPOSITE PARTICLES; CHITOSAN NANOPARTICLES;
D O I
10.2217/NNM.10.143
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Peptides and therapeutic proteins have been the target of intense research and development in recent years by the pharmaceutical and biotechnology industry. Preferably, they are administered through the parenteral route, which is associated with reduced patient compliance. Formulations for noninvasive administration of peptides and therapeutic proteins are currently being developed. Among them, inhalation appears as a promising alternative for the administration of such products. Several formulations for pulmonary delivery are in various stages of development. Despite positive results, conventional formulations have some limitations such as reduced bioavailability and side effects. Nanocarriers may be an alternative way to overcome the problems of conventional formulations. Some nanocarrier-based formulations of peptides and therapeutic proteins are currently under development. The results obtained are promising, revealing the usefulness of these systems in the delivery of such drugs.
引用
收藏
页码:123 / 141
页数:19
相关论文
共 137 条
[1]   PULMONARY DELIVERY OF PEPTIDE DRUGS - EFFECT OF PARTICLE-SIZE ON BIOAVAILABILITY OF LEUPROLIDE ACETATE IN HEALTHY MALE-VOLUNTEERS [J].
ADJEI, A ;
GARREN, J .
PHARMACEUTICAL RESEARCH, 1990, 7 (06) :565-569
[2]   BIOAVAILABILITY OF LEUPROLIDE ACETATE FOLLOWING NASAL AND INHALATION DELIVERY TO RATS AND HEALTHY HUMANS [J].
ADJEI, A ;
SUNDBERG, D ;
MILLER, J ;
CHUN, A .
PHARMACEUTICAL RESEARCH, 1992, 9 (02) :244-249
[3]  
Agu RU, 2001, RESP RES, V2, P198
[4]  
Altorki NK, 1998, J THORAC CARDIOV SUR, V115, P36
[5]   Chitosan-based delivery systems for protein therapeutics and antigens [J].
Amidi, Maryam ;
Mastrobattista, Enrico ;
Jiskoot, Wim ;
Hennink, Wim E. .
ADVANCED DRUG DELIVERY REVIEWS, 2010, 62 (01) :59-82
[6]   Therapeutic application of peptides and proteins: parenteral forever? [J].
Antosova, Zuzana ;
Mackova, Martina ;
Kral, Vladimir ;
Macek, Tomas .
TRENDS IN BIOTECHNOLOGY, 2009, 27 (11) :628-635
[7]   Pulmonary pharmacokinetics of cyclosporin A liposomes [J].
Arppe, J ;
Vidgren, M ;
Waldrep, JC .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1998, 161 (02) :205-214
[8]   Targeted delivery of nanoparticles for the treatment of lung diseases [J].
Azarmi, Shirzad ;
Roa, Wilson H. ;
Loebenberg, Raimar .
ADVANCED DRUG DELIVERY REVIEWS, 2008, 60 (08) :863-875
[9]   Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles [J].
Azarmi, Shirzad ;
Tao, Xia ;
Chen, Hua ;
Wang, Zhaolin ;
Finlay, Warren H. ;
Lobenberg, Raimar ;
Roa, Wilson H. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2006, 319 (1-2) :155-161
[10]   Functional characterization of the peptide transporter PEPT2 in primary cultures of human upper airway epithelium [J].
Bahadduri, PM ;
D'Souza, VM ;
Pinsonneault, JK ;
Sadée, W ;
Bao, SY ;
Knoell, DL ;
Swaan, PW .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2005, 32 (04) :319-325